SAVA Stock: Cassava Sciences' Alzheimer's Drug Fails. Stock Plummets 83%.

Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.

The experimental treatment, simufilam, has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June.---9:36 AM ET, 11/25/2024 - Reuters

Seeking Alpha: Cassava Sciences stock tumbles as CEO Remi Barbier resigns (NASDAQ:SAVA)
Cassava Sciences (SAVA) announces changes in executive leadership and enhanced corporate governance, leading to a 27% plunge in premarket...
- Cassava Sciences Inc currently has a Risk Rating of 1, which is
significantly below the S&P 500 index average rating of 8.9.
- On days when the market is up, SAVA tends to outperform the
S&P 500 index. However, on days when the market is down,
the shares generally decrease by less than the index.
- In both short-term and long-term periods, SAVA has shown low
correlation (greater & = -0.1 and less than 0.2%) with the S&P 500 index. Thus,
this stock would provide high levels of diversification to a
portfolio similar to the broader market.
- Over the last 90 days, SAVA shares have been more volatile
than the overall market. The stock's daily price fluctuations
have exceeded that of all S&P 500 index firms.
Cassava Sciences Refutes 'Egregious Misconduct' Allegations in CUNY Report, Calls Findings 'Illegitimate'; Shares Slump. MT Newswires 10:40 AM ET, Friday 10/13/2023.

SAVA remains in a bearish trend despite trading above the 200-day moving average. Its MACD is beneath the signal line and the overall trend of this security is lower. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500. As of 4:00 PM ET Thursday, 10/14/2022

Cassava Sciences stock SAVA is currently one of the most contentious
publicly trade US stock as of today the 27th of Dec. 2021.
The controversy and allegations of data manipulation goes all the way
back to 2005.
Two academic journals have cleared the company of any manipulation the
latest being the Neuroscience journal and the other the Journal of
Neuroscience.
Remi Barbier, President & CEO stated recently:
This reinforces my conviction that false and misleading allegations of
scientific misconduct being made against us are simply designed to
enrich those making them.

Simufilam is a new oral drug candidate from Cassava Sciences for the
proposed treatment of mild-to-moderate Alzheimer's disease.
On the 23rd of Dec.2021 Cassava Sciences announced the launch of a new
clinical website, called www.Rethink-ALZ.com.
Rethink-ALZ.com is intended to provide access, visibility and
information on Cassava Sciences' Phase 3 safety and efficacy studies of
oral simufilam

Over 25 clinical sites across the US are now participating in this Phase
3 efficacy studies of Simufilam in Alzheimer's disease.

Catalysts
Improving the eligibility criteria for participation in its Expanded
Access clinical trial

Broadening of its criteria as it concerns RethinkALZ and RefocusALZ
Clinical Research Studies

Any hint that advanced and severe Alzheimer's disease can be
acommodated in these trials or subsequent ones.

Early approval of the drug Simufilam and if there is hope for treating
Alzheimer's Disease

sava stock news
cassava sciences
sava stock buy or sell
sava stock forecast 2025
sava stocktwits
sava stock reddit
sava stock discussion
Is Sava a buy or sell?
Is Sava overvalued?
Why did Sava stock go down?
Who owns Sava stock?
sava stock catalyst
cassava sciences fda approval
sava stock discussion
sava stock forecast 2025
sava news release
sava ad
sava stock news
cassava sciences
sava clinical trials

[hir]

i lost a lot of money with it. Its i basically a100% loss so why should i sell it when i have nothing to lose anymore. I decide to hold it maybe it will go up again.